Reviewer's report

**Title:** Systematic evaluation of the methodology of randomized controlled trials of anticoagulation in patients with cancer

**Version:** 1 **Date:** 6 October 2012

**Reviewer:** Gregory Connolly

**Reviewer's report:**

This is a systemic evaluation of randomized controlled trials of anticoagulation in patients with cancer. The general design is sound and this addresses an interesting area of research with limited studies.

The paper is well written.

**Compulsory revisions:**

1) Anticoagulants are studied in cancer patients for various purposes. Specifically for treatment of VTE, prevention of VTE, and as anticancer agents. This is a critical component of the study design and there may be significant differences in studies due to this factor. The authors should provide information on the underlying objective of the studies and report whether there is difference in bias based on this.

2) Were there differences in incidence of outcomes reported based on funding source or degree of bias. In other words were industry sponsor studies reporting lower risk of bleeding complications.

**Level of interest:** An article whose findings are important to those with closely related research interests

**Quality of written English:** Acceptable

**Statistical review:** Yes, but I do not feel adequately qualified to assess the statistics.

**Declaration of competing interests:**

'I declare that I have no competing interests